These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 3499316)

  • 1. Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins.
    Dworzack DL; Pugsley MP; Sanders CC; Horowitz EA
    Eur J Clin Microbiol; 1987 Aug; 6(4):456-9. PubMed ID: 3499316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins.
    Sanders WE; Sanders CC
    Rev Infect Dis; 1988; 10(4):830-8. PubMed ID: 3055176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The threat of resistance to the new oral cephalosporins.
    Cullmann W
    Chemotherapy; 1992; 38 Suppl 2():10-7. PubMed ID: 1516458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical importance of inducible beta-lactamases in gram-negative bacteria.
    Sanders CC; Sanders WE
    Eur J Clin Microbiol; 1987 Aug; 6(4):435-8. PubMed ID: 3311737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.
    Livermore DM
    Eur J Clin Microbiol; 1987 Aug; 6(4):439-45. PubMed ID: 3311738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of beta-lactamase inducibility and derepression on the activity of cefpirome against gram-negative bacteria.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1993 Oct; 32(4):651-2. PubMed ID: 8288508
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence of inducible beta-lactamases in gram-negative septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.
    Eur J Clin Microbiol; 1987 Aug; 6(4):460-6. PubMed ID: 3117535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of resistance in gram-negative bacteria: a risk of broad-spectrum beta-lactam use.
    Dworzack DL
    Drug Intell Clin Pharm; 1986; 20(7-8):562-7. PubMed ID: 3488894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do beta-lactamases mean for clinical efficacy?
    Neu HC
    Infection; 1983; 11 Suppl 2():S74-80. PubMed ID: 6423546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-Lactam susceptibility patterns and investigation of cephalosporin hydrolysing beta-lactamases of Gram-negative extraintestinal clinical isolates.
    Gál Z; Szabó D; Kovács P; Hernádi F; Tóth-Martinez B; Rozgonyi F
    Int J Antimicrob Agents; 2000 Dec; 16(4):395-400. PubMed ID: 11118847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Resistance of gram negative bacteria to new generation cephalosporins and the role of beta-lactamases in this type of resistance].
    Gür D; Akalin HE; Baykal M
    Mikrobiyol Bul; 1988; 22(3):193-8. PubMed ID: 3266970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of extended spectrum beta lactamases production with cephalosporin resistance in gram negative bacilli.
    Ghatole M; Manthalkar P; Kandle S; Yemul V; Jahagirdar V
    Indian J Pathol Microbiol; 2004 Jan; 47(1):82-4. PubMed ID: 15471144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime: the next generation?
    Sanders CC
    Clin Infect Dis; 1993 Sep; 17(3):369-79. PubMed ID: 8218678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
    Pfeifer Y; Cullik A; Witte W
    Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects on beta-lactam susceptibility of phenotypic induction and genotypic derepression of beta-lactamase synthesis.
    Shannon K; Phillips I
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():15-22. PubMed ID: 3102451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for extended-spectrum beta-lactamase-producers.
    Essack SY
    FEMS Microbiol Lett; 2000 Sep; 190(2):181-4. PubMed ID: 11034276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactamases: current situation and clinical importance.
    Garau J
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S5-9. PubMed ID: 7962990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro expression of beta-lactam-induced response by clinical gram-negative bacteria with the potential for inducible beta-lactamase production.
    Bongaerts G; Roelofs-Willemse H
    Scand J Infect Dis; 1998; 30(6):579-83. PubMed ID: 10225386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.